| pubmed-article:21522147 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21522147 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:21522147 | lifeskim:mentions | umls-concept:C0728747 | lld:lifeskim |
| pubmed-article:21522147 | lifeskim:mentions | umls-concept:C0449258 | lld:lifeskim |
| pubmed-article:21522147 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:21522147 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:21522147 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:21522147 | pubmed:dateCreated | 2011-5-25 | lld:pubmed |
| pubmed-article:21522147 | pubmed:abstractText | Recent UK clinical guidance advises against continuing trastuzumab (T) beyond disease progression (PD) in the absence of brain metastases in patients with HER-2 positive (+ve) advanced breast cancer .We have retrospectively evaluated the outcome of patients with HER-2+ve locally advanced (LA) or metastatic breast cancer (MBC) who continued T beyond PD, treated in our unit. | lld:pubmed |
| pubmed-article:21522147 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21522147 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21522147 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21522147 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21522147 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21522147 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21522147 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21522147 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21522147 | pubmed:month | May | lld:pubmed |
| pubmed-article:21522147 | pubmed:issn | 1532-1827 | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:O'BrienMM | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:SmithII | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:AllenMM | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:PapadopoulosP... | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:JohnstonSS | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:AshleySS | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:WaddellTT | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:StarlingNN | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:YousafNN | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:Constantinido... | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:PartonMM | lld:pubmed |
| pubmed-article:21522147 | pubmed:author | pubmed-author:KotsoriAA | lld:pubmed |
| pubmed-article:21522147 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21522147 | pubmed:day | 24 | lld:pubmed |
| pubmed-article:21522147 | pubmed:volume | 104 | lld:pubmed |
| pubmed-article:21522147 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21522147 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21522147 | pubmed:pagination | 1675-9 | lld:pubmed |
| pubmed-article:21522147 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:meshHeading | pubmed-meshheading:21522147... | lld:pubmed |
| pubmed-article:21522147 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21522147 | pubmed:articleTitle | Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience. | lld:pubmed |
| pubmed-article:21522147 | pubmed:affiliation | Breast Unit Royal Marsden Hospital, Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK. | lld:pubmed |
| pubmed-article:21522147 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21522147 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
